Results 21 to 30 of about 5,736 (192)

Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases [PDF]

Trends in Pharmaceutical Sciences
Thalassemia is a genetic disease that significantly affects human health. The common treatment of thalassemia is the regular injection of red blood cell, which is associated with the accumulation of iron in different tissues of the body, and makes ...
Sara Sadeghian, Fateme Zare, Lotfollah Saghaie, Razieh Sabet   +3 more
doaj   +1 more source

Perbedaan Kadar Thyroid Stimulating Hormone dan Free Thyroxine pada Pasien Talasemia Β-Mayor dengan Kelasi Besi Deferasirox dan Deferiprone

Sari Pediatri, 2018
Latar belakang. Talasemia β Mayor merupakan kelainan herediter yang disebabkan gangguan produksi rantai globin. Transfusi rutin menyebabkan kelebihan besi yang tertimbun dalam jaringan sehingga menyebabkan kardiomiopati, gangguan liver, dan komplikasi ...
Aries - Krisbiyantoro, Harsono Salimo, Annang Giri Moelyo   +2 more
doaj   +1 more source

Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression

, 2022
Depressed individuals who carry the short allele for the serotonin-transporter-linked promotor region of the gene are more vulnerable to stress and have reduced response to first-line antidepressants such as selective serotonin reuptake inhibitors. Since
Hale, MW, Aitken, C, Uzungil, V, Tran, H, Bush, AI, Renoir, T, Payet, JM, Wilson, C, Opazo, CM, Li, S, Mawal, CH, Hannan, AJ   +11 more
core   +2 more sources

Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. [PDF]

, 2008
Background: Cardiac iron overload is the leading cause of death in thalassemia major and is usually assessed using myocardial T2* measurements. Recently a cardiovascular magnetic resonance (CMR) breath-hold T2 sequence has been developed as a possible ...
Tan, RS, Tan Ru, Chan, G.C.F, He, T, Fogel Mark A, Firmin David N, Au, W-Y, Pennell, Dudley J., Chan, GCF, Fogel, MA, Lam, W.M, Aydinok, Y, Chu, WCW, He, Taigang, Cohen, AR, Ng, I, Chu Winnie CW, Cohen, Alan R., Pennell, DJ, Pennell Dudley J, Firmin, D.N, Chu, W.C.W, Biceroglu, S, Fogel, M.A, Tan, R.S, Lam, WM, Chan Godfrey CF, Lam Wynnie M, Firmin, David N., Biceroglu Selen, Aydinok Yesim, Aydinok, Yesim, Firmin, DN, Kirk, Paul, Fogel, Mark A., Pennell, D.J, Ng Ivy, Kirk, P, Au, Wing-Yan, Tan, Ru San, Au, WY, He Taigang, Kirk Paul, Chan, GC, Biceroglu, Selen, Cohen, A.R, Au Wing-Yan, Chu, Winnie C. W., Chu, WC, Au, W.-Y, Lam, Wynnie M., Cohen Alan R, Ng, Ivy, Chan, Godfrey C. F.   +53 more
core   +1 more source

Chelation Combination—A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?

Biomolecules, 2022
The chelating thiol dimercaptosuccinate (DMSA) and the traditional agent D-penicillamine (PSH) are effective in enhancing the urinary excretion of copper (Cu) and lead (Pb) in poisoned individuals. However, DMSA, PSH, EDTA (ethylenediamine tetraacetate),
Jan O. Aaseth, Valeria M. Nurchi
doaj   +1 more source

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.

JAMA Neurol
IMPORTANCE: Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide.
Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, Devos D, Ellis KA, Fazlollahi A, Fradette C, Goh AMY, Kalinowski P, Kyndt C, Lai R, Lim YY, Maruff P, O'Brien TJ, Rowe C, Salvado O, Schofield PW, Spino M, Tricta F, Wagen A, Williams R, Woodward M, Bush AI.   +25 more
europepmc   +2 more sources

Chelator-facilitated removal of iron from transferrin: Relevance to combined chelation therapy

, 2007
Current iron chelation therapy consists primarily of DFO (desferrioxamine), which has to be administered via intravenous infusion, together with deferiprone and deferasirox, which are orally-active chelators.
Hider, Robert C, Evans, PJ, Evans, Robert W, Evans, Patricia J, Evans, RW, Hider, R C, Devanur, Lakshmi D, Hider, RC, Devanur, L D, Devanur, LD, Evans, P J, Evans, R W   +11 more
core   +1 more source

Synergistic Effects of Nanoemulsion and Deferiprone (1, 2 Dimethyl-3-Hydroxypyrid-4-One) on Multi-Drug Resistant Acinetobacter baumannii

Nano Biomedicine and Engineering, 2019
Nosocomial infections caused by Acinetobacter baumannii (A. baumannii) are exceedingly difficult to treat, particularly in immune-compromised patients. Nanoemulsions (NEs) are a distinctive category of disinfectants that have wide range of bactericidal ...
Karthikeyan Ramalingam, Valerie Lee
doaj   +1 more source

Effect of deferiprone on cell cytotoxicity.

, 2015
(A) Light microscopic images on day 0 shows an equal number of PBMCs for each group. (B) LDH release by PBMC after treatment with deferiprone for 8 days.
Oleg Karaduta (787139), Judit K. Megyesi (456448), Sudhir V. Shah (787136), Kim M. Hiatt (787137), Chhanda Bose (787135), Kimberly A. Hall (787138), Sundararaman Swaminathan (787140)   +6 more
core   +1 more source

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Scientific Reports, 2017
Parkinson’s disease (PD) is associated with increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron from various brain regions and improve PD symptomology ...
Antonio Martin-Bastida, Roberta J. Ward, Rexford Newbould, Paola Piccini, David Sharp, Christina Kabba, Maneesh C. Patel, Michael Spino, John Connelly, Fernando Tricta, Robert R. Crichton, David T. Dexter   +11 more
doaj   +1 more source